Sinovac establishes joint venture to expand vaccine development, manufacturing

BEIJING — Sinovac Biotech Ltd. announced Nov. 25 that it executed a joint venture agreement to establish Sinovac (Dalian) Vaccine Technology Co. Ltd. to research, develop, produce and commercialize human-use vaccines.

Sinovac will contribute its expertise and experience in developing and commercializing vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

The agreement “enables Sinovac to cost effectively establish manufacturing platforms for live attenuated vaccines and vero cell cultured vaccines, thus adding another important manufacturing site for Sinovac's vaccine products,” said Weidong Yin, chairman, president and CEO of Sinovac. 

Sinovac Dalian will be headquartered in Dalian, Liaoning province, China, and will occupy a campus of approximately 1 million square feet.

Based on current projections, Sinovac Dalian's development pipeline is expected to be comprised of vaccines for rabies, mumps, varicella and rubella. The Dalian-based facility has a designed annual manufacturing capacity of 20 million doses of vero cell cultured vaccines and 20 million doses of live attenuated vaccines.